DOT1L and leukemia: AdoMet-competitive DOT1L inhibitors selectively kill mixed lineage leukemia cells, prolong survival in a mouse xenograft model of MLL-rearranged leukemia and have been in clinical trials (e.g. Pinometostat) (Daigle et al., 2011, 2013).